The Readout

The Readout By Damian Garde

Biotech is swimming in cash, SoftBank remains generous, & Sanofi starts a nonprofit

The Readout By Damian Garde

Acadia’s FDA issues deepen, Novavax’s impending data, & Moderna’s security budget

The Readout By Damian Garde

Emergent’s PR crisis, STAT Madness winners, & sour times for SPACs

The Readout By Meghana Keshavan

A new Covid-19 vaccine trial for kids, Pfizer’s painful panel, & a Novartis gene therapy plant will shutter

The Readout By Damian Garde

AstraZeneca confirms vaccine efficacy, Covid lined CROs’ pockets, & Pfizer’s FDA moment

The Readout By Damian Garde

AstraZeneca’s PR crisis, panic among biotech investors, & allegations of pharma subterfuge

The Readout By Damian Garde

Regeneron’s antibody shines in Covid study, Roche halts Huntington’s trial, & a momentous FDA meeting

The Readout By Meghana Keshavan

AstraZeneca’s long-awaited results, calling the Covid-19 race, & RIP José Baselga

The Readout By Meghana Keshavan

SEC charges former uBiome execs, the power of drug names, & a biotech bestseller

The Readout By Damian Garde

The post-Trump FDA, an mRNA disappointment, & a better mousetrap in Alzheimer’s

The Readout By Damian Garde

Pharma megamergers could be in danger, FibroGen faces the FDA, & gene therapy remains lucrative

The Readout By Damian Garde

Rubius doubles on early data, AstraZeneca faces a confidence crisis, & Lilly’s data feeds a debate

The Readout By Meghana Keshavan

ElevateBio bags $525M, Lilly’s strong data polarizes, & Bourla is bummed

The Readout By Meghana Keshavan

Sanofi’s mRNA entrance, strong Novavax results, & can patent law tame prices?

The Readout By Meghana Keshavan

A reprieve for Bluebird, rising antibiotic prices, & breaking code with Isaacson

The Readout By Meghana Keshavan

Effects of an FDA vacuum, Quench’s ‘successful failure,’ & a possible Abbisko IPO

The Readout By Meghana Keshavan

Takeda buys Maverick, PhRMA pleads with WTO, & resuscitating Rubius?

The Readout By Meghana Keshavan

CEPI on global vaccine plans, fact-checking Biden’s new timeline, & CytoDyn’s flop

The Readout By Meghana Keshavan

Five Prime goes for $1.9B, Lilly’s Alzheimer’s drug, & the cost of neglecting generics

The Readout By Damian Garde

Lilly’s coup in diabetes treatment, Vir’s double standard, & a rare bad day for biotech

The Readout By Damian Garde

Ovid’s second act, Merck’s collaborative spirit, & peace among the CRISPRers

The Readout By Damian Garde

Fibrogen’s last-minute delay, Novavax’s plan for variants, & an idea to regulate drug costs

The Readout By Meghana Keshavan

Woodcock’s record, Finch’s $100M IPO, & AstraZeneca partners with Junshi

The Readout By Meghana Keshavan

Sarepta scores again with Duchenne, unraveling biologic patents, & Tal Zaks heads for the exits